Mustang Bio, Inc. (MBIO) Dividend History

Company News

• Mustang Bio Announces Closing of $8 Million Public Offering

  Mustang Bio, a clinical-stage biopharmaceutical company, announced the closing of a public offering of common stock and warrants, raising approximately $8 million. The company plans to use the proceeds for working capital and general corporate purposes.

  GlobeNewswire Inc.

  Featured Companies: FBIO FBIOP
• Mustang Bio Announces Pricing of $8 Million Public Offering

  Mustang Bio, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of $8 million, which it plans to use for working capital and general corporate purposes.

  Benzinga

  Featured Companies: FBIO FBIOP
• Fortress Biotech CEO buys $36.7k in preferred stock - Investing.com

  Fortress Biotech CEO Dr. Lindsay A. Rosenwald has increased his stake in the company by purchasing $36.7k worth of Series A Cumulative Perpetual Preferred Stock. This move demonstrates the CEO's confidence in the company's future prospects.

  Investing.com

  Featured Companies: FBIO FBIOP
• Navigating Bull and Bear Penny Stocks Markets, 3 Tips

  Use these top tips to navigate the bull and bear penny stocks market The post Navigating Bull and Bear Penny Stocks Markets, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: NLSP
• Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study

  Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.

  Zacks Investment Research

  Featured Companies: ABBV JNJ